



ASX Announcement and Media Release

6 August 2018

SciGen Ltd

CONFIRMATION OF DELISTING TIMETABLE

1. Introduction

The board of directors (the “**Board**” or the “**Directors**”) of SciGen Ltd (the “**Company**”) refers to the announcement dated 9 July 2018 issued by SAC Capital Private Limited, for and on behalf of Yifan International Pharmaceutical Co., Limited (the “**Offeror**”), relating to the despatch of the formal offer document (the “**Offer Document**”) containing the terms and conditions of the voluntary conditional general offer (the “**Offer**”) for all the issued and paid-up ordinary shares in the capital of the Company (excluding treasury shares) (the “**Shares**”), other than those Shares already owned, controlled, or agreed to be acquired by the Offeror, but including Shares owned, controlled, or agreed to be acquired by parties acting or deemed to be acting in concert with the Offeror.

As part of the Offer, it is intended that the Company be delisted from the ASX.

All capitalised terms used and not defined herein shall have the same meanings ascribed to them in the Offer Document (as defined herein), unless otherwise expressly stated or the context otherwise requires. For the avoidance of doubt, “Compulsory Acquisition” as used herein refers to the compulsory acquisition which the Offeror intends to carry out as set out in Paragraph 9.2 of the Offer Document.

2. Confirmation of Delisting Timetable

The Board wishes to inform Shareholders that it is intending to implement the delisting of the Company from the ASX in accordance with the timetable below:

Date	Event
21 August 2018	Subject to the Companies Act, the Offeror announces it has exercised Compulsory Acquisition rights following the end of the objection period for Dissenting Shareholders under the Companies Act. The Offeror will formally notify the ASX that its Compulsory Acquisition rights have been exercised.
22 August 2018	ASX will suspend the Company's CDIs from trading.
27 August 2018	Settlement of the Compulsory Acquisition exercise to occur. All remaining CDIs on issue will be transferred to the Offeror in exchange for payment to be made by the CDIs Receiving Agent.
28 August 2018	ASX will remove the Company from the official list at the close of trading.

3. Responsibility Statement

The Directors (including those who have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and opinions expressed in this announcement are fair and accurate, and that there are no other material facts not contained in this announcement, the omission of which would make any statement in this announcement misleading, and they jointly and severally accept responsibility accordingly. Where any information has been extracted or reproduced from published or otherwise publicly available sources, the sole responsibility of the Directors has been to ensure through reasonable enquiries that such information is accurately extracted from such sources or, as the case may be, reflected or reproduced in this announcement.

BY ORDER OF THE BOARD

For and on behalf of SciGen Ltd

Marek Dziki

6 August 2018

About SciGen Limited

SciGen Ltd (“SciGen”) is a biopharmaceutical company involved in sales and marketing of genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of endocrinology, paediatrics and oncology-care.

Its core product portfolio consists of biosimilar products, notably, recombinant human insulin and recombinant human growth hormone which have undergone substantial clinical development. SciGen has since built a diversified portfolio in recent years, comprising endocrinology, neurology, oncology-care products, paediatric supplements, orthopaedic injection therapy and a range of medical devices.

SciGen has acquired the rights to distribute and market biopharmaceutical and proprietary products under both exclusive and semi-exclusive licensing arrangements. SciGen’s current focus is in the Asia Pacific region which provides growth opportunities for its range of products.

SciGen currently maintains internal sales and marketing teams at its subsidiary offices, whilst venturing into distribution partnerships in other markets. Through joint collaboration with its partners, SciGen uses its extensive expertise in regulatory and clinical environments, to cater to a broader spectrum of market.

SciGen was established in 1988, as a Singapore biopharmaceutical company. SciGen is listed on the Australian Stock Exchange (ASX code : SIE). Its corporate headquarters is located in Singapore, with subsidiary offices in Australia, South Korea, China and a sales office in Philippines. Strategic distribution channels are present in Thailand, Hong Kong, Pakistan, Indonesia, Singapore, Bangladesh, Myanmar and Vietnam.

For further information: Company - Investor Relations	Company
Mr. Martin Naef SciGen (Australia) Pty Ltd +61 2 9485 1800 E-mail : MNaef@scigen.com.au	Ms. Yvonne Lim SciGen Ltd +65 6779 6638 E-mail : central@scigen.com.sg